Literature DB >> 12920167

Glucuronidation of anabolic androgenic steroids by recombinant human UDP-glucuronosyltransferases.

Tiia Kuuranne1, Mika Kurkela, Mario Thevis, Wilhelm Schänzer, Moshe Finel, Risto Kostiainen.   

Abstract

A multidimensional study on the glucuronidation of anabolic androgenic steroids and their phase I metabolites by 11 recombinant human UDP-glucuronosyltransferases (UGTs) was carried out using liquid chromatographic-tandem mass spectrometric analyses. Large differences between the enzymes with respect to the conjugation profiles of the 11 tested aglycones were detected. Two UGTs, 1A6 and 1A7, did not exhibit measurable activity toward any of the aglycones that were examined in this study. Regioselectivity was demonstrated by UGTs 1A8, 1A9, and 2B15 that preferentially catalyzed hydroxyl glucuronidation at the 17beta-position. Most of the other enzymes glucuronidated hydroxyl groups at both the 3alpha- and the 17beta-positions. Clear stereoselectivity was observed in glucuronidation of diastereomeric nandrolone metabolites (5alpha-estran-3alpha-ol-17-one and 5beta-estran-3alpha-ol-17-one), whereas such specificity was not seen when analogous methyltestosterone metabolites were assayed. UGTs 1A1, 1A3, 1A4, 1A8, 1A9, 1A10, 2B4, 2B7, and 2B15 readily glucuronidated 5alpha-androstane-3alpha,17beta-diol, but none of them exhibited methyltestosterone glucuronidation activity. In agreement with the latter observations, we found that the methyltestosterone glucuronidation activity of human liver microsomes is extremely low, whereas in induced rat liver microsomes it was significantly higher. The homology among UGTs 1A7 to 1A10 at the level of amino acid sequence is very high, and it was thus surprising to find large differences in their activity toward this set of aglycones. Furthermore, the high activity of UGT1A8 and 1A10 toward some of the substrates indicates that extrahepatic enzymes might play a role in the metabolism of anabolic androgenic steroids.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12920167     DOI: 10.1124/dmd.31.9.1117

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  21 in total

1.  Phenylalanine(90) and phenylalanine(93) are crucial amino acids within the estrogen binding site of the human UDP-glucuronosyltransferase 1A10.

Authors:  Athena Starlard-Davenport; Yan Xiong; Stacie Bratton; Anna Gallus-Zawada; Moshe Finel; Anna Radominska-Pandya
Journal:  Steroids       Date:  2006-12-15       Impact factor: 2.668

2.  Conjugation of synthetic cannabinoids JWH-018 and JWH-073, metabolites by human UDP-glucuronosyltransferases.

Authors:  Krishna C Chimalakonda; Stacie M Bratton; Vi-Huyen Le; Kan Hui Yiew; Anna Dineva; Cindy L Moran; Laura P James; Jeffery H Moran; Anna Radominska-Pandya
Journal:  Drug Metab Dispos       Date:  2011-07-11       Impact factor: 3.922

3.  Effects of UGT1A9 genetic polymorphisms on monohydroxylated derivative of oxcarbazepine concentrations and oxcarbazepine monotherapeutic efficacy in Chinese patients with epilepsy.

Authors:  Yao Lu; Youxin Fang; Xunyi Wu; Chunlai Ma; Yue Wang; Lan Xu
Journal:  Eur J Clin Pharmacol       Date:  2016-11-29       Impact factor: 2.953

4.  Phenylalanine 93 of the human UGT1A10 plays a major role in the interactions of the enzyme with estrogens.

Authors:  Camilla Höglund; Nina Sneitz; Anna Radominska-Pandya; Liisa Laakonen; Moshe Finel
Journal:  Steroids       Date:  2011-08-09       Impact factor: 2.668

5.  Natural prenylated resveratrol analogs arachidin-1 and -3 demonstrate improved glucuronidation profiles and have affinity for cannabinoid receptors.

Authors:  Lisa K Brents; Fabricio Medina-Bolivar; Kathryn A Seely; Vipin Nair; Stacie M Bratton; Luis Nopo-Olazabal; Ronak Y Patel; Haining Liu; Robert J Doerksen; Paul L Prather; Anna Radominska-Pandya
Journal:  Xenobiotica       Date:  2011-10-04       Impact factor: 1.908

6.  Analysis of R- and S-hydroxywarfarin glucuronidation catalyzed by human liver microsomes and recombinant UDP-glucuronosyltransferases.

Authors:  Stacie M Bratton; Carrie M Mosher; Farid Khallouki; Moshe Finel; Michael H Court; Jeffery H Moran; Anna Radominska-Pandya
Journal:  J Pharmacol Exp Ther       Date:  2011-10-04       Impact factor: 4.030

7.  Potentially harmful advantage to athletes: a putative connection between UGT2B17 gene deletion polymorphism and renal disorders with prolonged use of anabolic androgenic steroids.

Authors:  Nawed Deshmukh; Andrea Petróczi; James Barker; Andrea D Székely; Iltaf Hussain; Declan P Naughton
Journal:  Subst Abuse Treat Prev Policy       Date:  2010-04-29

8.  Glucuronidation of monohydroxylated warfarin metabolites by human liver microsomes and human recombinant UDP-glucuronosyltransferases.

Authors:  Agnieszka Zielinska; Cheryl F Lichti; Stacie Bratton; Neil C Mitchell; Anna Gallus-Zawada; Vi-Huyen Le; Moshe Finel; Grover P Miller; Anna Radominska-Pandya; Jeffery H Moran
Journal:  J Pharmacol Exp Ther       Date:  2007-10-05       Impact factor: 4.030

9.  A potential role for human UDP-glucuronosyltransferase 1A4 promoter single nucleotide polymorphisms in the pharmacogenomics of tamoxifen and its derivatives.

Authors:  Aleksandra K Greer; Centdrika R Dates; Athena Starlard-Davenport; Vineetha K Edavana; Stacie M Bratton; Ishwori B Dhakal; Moshe Finel; Susan A Kadlubar; Anna Radominska-Pandya
Journal:  Drug Metab Dispos       Date:  2014-06-10       Impact factor: 3.922

10.  Evidence for oxazepam as an in vivo probe of UGT2B15: oxazepam clearance is reduced by UGT2B15 D85Y polymorphism but unaffected by UGT2B17 deletion.

Authors:  Xi He; Leah M Hesse; Suwagmani Hazarika; Gina Masse; Jerold S Harmatz; David J Greenblatt; Michael H Court
Journal:  Br J Clin Pharmacol       Date:  2009-11       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.